Autoimmune neurologic diseases

Poster

Baff Expands Circulating Transitional B Cells in Multiple Sclerosis Patients Treated with Fingolimod

Friday, June 16
6:15 PM - 7:30 PM

Background: Fingolimod is a sphingosine-1-phosphate receptor agonist used as a disease-modifying drug for multiple sclerosis (MS). We have previously shown that MS patients treated with fingolimod have an increased proportion of circulating transitional B cells, but the underlying mechanism remains unknown. B cell-activating factor of the TNF family (BAFF) is a cytokine involved in the differentiation and proliferation of B cells. Mice overexpressing BAFF have been shown to have increased numbers of transitional B cells; therefore, we hypothesized that BAFF is involved in an increase in transitional B cells in MS patients treated with fingolimod. Subjects and methods: Serum samples were collected from 25 healthy subjects, 32 untreated MS patients, and 30 MS patients treated with fingolimod. Concentrations of BAFF in serum were quantified by ELISA. In addition, alterations in serum BAFF levels after starting fingolimod were analyzed in three treatment-naïve MS patients. The proportions of B cell subsets in 14 MS patients treated with fingolimod were determined by flow cytometry, and the relationships between serum BAFF concentrations and each B cell subset were analyzed. Results: Serum concentrations of BAFF were significantly higher in fingolimod-treated MS patients than in healthy subjects or untreated MS patients (p < 0.001). Serum levels of BAFF rose significantly after starting fingolimod treatment in the longitudinal study (p=0.014). A significant positive correlation was found between the serum concentration of BAFF and the percentage of transitional B cells (p=0.0244). Conclusion: BAFF is involved in the increase in circulating transitional B cells in MS patients treated with fingolimod.

Yusei Miyazaki

Post-doc
Hokkaido Medical Center

Presentation(s):

    Send Email for Yusei Miyazaki

    Masaaki Niino

    Hokkaido Medical Center

    Presentation(s):

      Send Email for Masaaki Niino

      Eri Takahashi

      Hokkaido Medical Center

      Presentation(s):

        Send Email for Eri Takahashi

        Itaru Amino

        Hokkaido Medical Center

        Presentation(s):

          Send Email for Itaru Amino

          Fumihito Nakano

          Hokkaido Medical Center

          Presentation(s):

            Send Email for Fumihito Nakano

            Masakazu Nakamura

            Hokkaido Medical Center

            Presentation(s):

              Send Email for Masakazu Nakamura

              Sachiko Akimoto

              Hokkaido Medical Center

              Presentation(s):

                Send Email for Sachiko Akimoto

                Naoya Minami

                Hokkaido Medical Center

                Presentation(s):

                  Send Email for Naoya Minami

                  Naoto Fujiki

                  Hokkaido Medical Center

                  Presentation(s):

                    Send Email for Naoto Fujiki

                    Shizuki Doi

                    Hokkaido Medical Center

                    Presentation(s):

                      Send Email for Shizuki Doi

                      Toshiyuki Fukazawa

                      Sapporo Neurology Hospital

                      Presentation(s):

                        Send Email for Toshiyuki Fukazawa

                        Seiji Kikuchi

                        Hokkaido Medical Center

                        Presentation(s):

                          Send Email for Seiji Kikuchi


                          Assets

                          Baff Expands Circulating Transitional B Cells in Multiple Sclerosis Patients Treated with Fingolimod



                          Attendees who have favorited this

                          Send Email for Baff Expands Circulating Transitional B Cells in Multiple Sclerosis Patients Treated with Fingolimod